Responses

other Versions

PDF
Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Topical non-steroidal anti-inflammatory drugs to prevent cystoid macular oedema after cataract extraction: Are they effective?
    • Andres B. Alberto, Resident in Ophthalmology
    • Other Contributors:
      • The Journal Club Group: Candelaria Pinto Herrera, Jacqueline Agustino Rodriguez, Denisse Angel Pereira, Alicia Pareja Rios, Eliseo Quijada Fumero, Luis Cordoves Dorta, Elena de Armas Ramos, Alejandro Jimenez Sosa, Valentin T. Diaz Aleman.

    We have read with interest the paper by Tzelikis et al. entitled: "Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo- controlled randomised study" [Br J Ophthalmol 2015;99(5):654-658].

    In order to consider as statistically similar the effects of ketorolac 0.4%, 0.1% nepafenac and placebo, the authors really needed to have...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Ketorolac does prevent retinal thickening and CME in routine cataract surgery

    Your study actually confirms the data that we reported in the lead article of the AJO in October 2008 showing the benefit of ketorolac in preventing CME and retinal thickening after routine cataract surgery. To demonstrate statistical significance for CME, it requires a sample size of close to 400 patients per group. Your data clearly shows a trend to decreased retinal thickening when a NSAID is used in conjunction with...

    Show More
    Conflict of Interest:
    None declared.